Get the Stockscreener App
0.435
7.78%
0.0314
After Hours:
.43
-0.005
-1.15%
Xortx Therapeutics Inc stock is traded at $0.435, with a volume of 84,749.
It is up +7.78% in the last 24 hours and up +7.89% over the past month.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$0.4036
Open:
$0.41
24h Volume:
84,749
Relative Volume:
0.89
Market Cap:
$3.03M
Revenue:
-
Net Income/Loss:
$-2.66M
P/E Ratio:
-0.7249
EPS:
-0.6001
Net Cash Flow:
$-2.83M
1W Performance:
+7.67%
1M Performance:
+7.89%
6M Performance:
-47.27%
1Y Performance:
-56.93%
1-Day Range:
$0.3793
$0.449
1-Week Range:
$0.3681
$0.449
52-Week Range:
$0.3681
$1.41
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.435 | 2.81M | 0 | -2.66M | -2.83M | -0.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders - Bitget
XORTX Therapeutics Completes Filing and Mailing of Documents for Annual and Special Shareholder Meeting - geneonline.com
XORTX seeks shareholder vote on up to 5-for-1 share consolidation - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
XORTX (NASDAQ: XRTX) seeks share consolidation to meet $1 bid - Stock Titan
XRTX Should I Buy - Intellectia AI
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XORTX Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
XRTXXortx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Sectors Review: Can XORTX Therapeutics Inc continue delivering strong returnsJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
What’s the beta of XORTX Therapeutics Inc. stockJuly 2025 Selloffs & Weekly High Return Opportunities - mfd.ru
Take Profit: What is the target price for XORTX Therapeutics Inc stock2025 Trade Ideas & Precise Trade Entry Recommendations - baoquankhu1.vn
XRTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can XORTX Therapeutics Inc. continue delivering strong returnsDay Trade & Reliable Price Action Trade Plans - mfd.ru
Is XORTX Therapeutics Inc. stock a buy before product launchesEarnings Performance Report & Smart Swing Trading Techniques - mfd.ru
Will XORTX Therapeutics Inc. outperform during market ralliesWeekly Stock Report & Growth Oriented Trade Recommendations - mfd.ru
Trading Action: What is XORTX Therapeutics Incs TAM Total Addressable MarketMarket Performance Recap & Verified Technical Signals - baoquankhu1.vn
XORTX Therapeutics Brief: Provided Overnight Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems - marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars - Nasdaq
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems - markets.businessinsider.com
Kidney drug deal: XORTX gets more time to close Vectus buy - Stock Titan
XORTX (NASDAQ: XRTX) extends VB4-P5 kidney fibrosis deal deadline - Stock Titan
Investor Mood: Why is OSBC stock going upRate Cut & Real-Time Price Movement Reports - baoquankhu1.vn
Travel Stocks: Whats the RSI of XORTX Therapeutics Inc stock2025 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
EPS Watch: Can XORTX Therapeutics Inc continue delivering strong returns - baoquankhu1.vn
Is XORTX Therapeutics Inc. a speculative investment2025 Market WrapUp & Weekly Consistent Profit Watchlists - mfd.ru
Does XORTX Therapeutics Inc. meet Warren Buffett’s criteriaWeekly Trend Report & Short-Term Trading Opportunity Alerts - mfd.ru
Earnings Miss: What is the target price for XORTX Therapeutics Inc stockInflation Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Treasury Yields: Does XORTX Therapeutics Inc meet Warren Buffetts criteriaJuly 2025 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
Market Fear: What is XORTX Therapeutics Incs TAM Total Addressable MarketJuly 2025 Momentum & AI Optimized Trade Strategies - baoquankhu1.vn
XORTX leans into genetic breakthroughs in gout as it reshapes board and advances oxypurinol - MSN
Dividend Watch: Is XORTX Therapeutics Inc vulnerable to short sellers2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Sentiment Recap: How XORTX Therapeutics Inc stock performs after earningsWeekly Trade Review & Reliable Momentum Entry Alerts - Bộ Nội Vụ
Is XORTX Therapeutics Inc. stock positioned well for digital economyOil Prices & Weekly Setup with ROI Potential - Улправда
Revenue per share of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView — Track All Markets
Why XORTX Therapeutics Inc. stock remains resilientJuly 2025 Intraday Action & Trade Opportunity Analysis Reports - Улправда
Is XORTX Therapeutics Inc. (ANUA) stock a buy before earnings resultsQuarterly Trade Review & Weekly Top Stock Performers List - ulpravda.ru
Will XORTX Therapeutics Inc. stock attract more institutional investors2025 Risk Factors & Long Hold Capital Preservation Tips - ulpravda.ru
Contact | Statesman-ExaminerXORTX Therapeutics Inc.Common Stock (Nasdaq:XRTX) Stock Quote - FinancialContent
XORTX Therapeutics : Investor Presentation - MarketScreener
Will XORTX Therapeutics Inc. stock beat EPS estimatesStock Split Announcements & High Profit Portfolio Growth - Улправда
Published on: 2026-01-07 21:30:14 - Улправда
XORTX highlights new gout genetics research, reshapes board and clarifies financing as Vectus deal nears closing - MSN
XORTX Leans Into Genetic Breakthroughs in Gout as It Reshapes Board and Advances Oxypurinol - TipRanks
Huge gout genetics study highlights target in kidney disease research - Stock Titan
XORTX Announces USD $3 Million Offering - 富途牛牛
Multi Factor Analysis Ranks Jaihind Synthetics Limited as Strong BuyInsider Selling Patterns & Lower Drawdowns With Smart Position Sizing - bollywoodhelpline.com
Order Book Volume Tilts Bullish on Adani Wilmar LimitedCurrency Fluctuation Impact & Breakout Stock Alerts - bollywoodhelpline.com
Chart Analysts Warn of Resistance Near Glance Finance Limited PriceCapital Gains Strategies & Small Capital Trading Plans - bollywoodhelpline.com
Fibonacci Levels Suggest Recovery for Johnson Pharmacare LimitedMomentum Trading Signals & Analysts Are Raving About These Shares - bollywoodhelpline.com
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):